Kuemmerle Deschner J, Wittkowski H, Tyrrell P, Koetter I, Lohse P, Ummenhofer K, et al
. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther. 2013;15:R64 pubmed
..Canakinumab led to a sustained control of disease activity even after secondary failure of anakinra therapy. S100A12 may be a sensitive marker to detect subclinical disease activity. ..